307 related articles for article (PubMed ID: 26576996)
1. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.
Meller B; Bremmer F; Sahlmann CO; Hijazi S; Bouter C; Trojan L; Meller J; Thelen P
EJNMMI Res; 2015 Dec; 5(1):66. PubMed ID: 26576996
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. 68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy.
Kesler M; Druckmann I; Levine C; Kuten J; Yossepowitch O; Even-Sapir E
Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33578990
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous
Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
[TBL] [Abstract][Full Text] [Related]
5.
Mesci A; Ahmadi E; Ali A; Gouran-Savadkoohi M; Evelyn Tsakiridis E; Biziotis OD; Chow T; Kapoor A; Sur M; Steinberg GR; Liu S; Zukotynski K; Tsakiridis T
Clin Transl Radiat Oncol; 2023 Mar; 39():100583. PubMed ID: 36713978
[TBL] [Abstract][Full Text] [Related]
6. Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer.
Bremmer F; Jarry H; Unterkircher V; Kaulfuss S; Burfeind P; Radzun HJ; Ströbel P; Thelen P
Oncotarget; 2018 Mar; 9(24):16951-16961. PubMed ID: 29682196
[TBL] [Abstract][Full Text] [Related]
7. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
Wright GL; Grob BM; Haley C; Grossman K; Newhall K; Petrylak D; Troyer J; Konchuba A; Schellhammer PF; Moriarty R
Urology; 1996 Aug; 48(2):326-34. PubMed ID: 8753752
[TBL] [Abstract][Full Text] [Related]
11. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.
Lückerath K; Wei L; Fendler WP; Evans-Axelsson S; Stuparu AD; Slavik R; Mona CE; Calais J; Rettig M; Reiter RE; Herrmann K; Radu CG; Czernin J; Eiber M
EJNMMI Res; 2018 Oct; 8(1):96. PubMed ID: 30374743
[TBL] [Abstract][Full Text] [Related]
13. [
Van Simaeys G; Doumont G; De Maeseneire C; Passon N; Lacroix S; Lentz C; Horion A; Warnier C; Torres D; Martens C; Vierasu I; Egrise D; Goldman S
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1773-1784. PubMed ID: 33398412
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC).
Bremmer F; Jarry H; Strauß A; Behnes CL; Trojan L; Thelen P
Springerplus; 2014; 3():574. PubMed ID: 25332874
[TBL] [Abstract][Full Text] [Related]
15. Preparation of
Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F
Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810
[TBL] [Abstract][Full Text] [Related]
16. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
17. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.
De Bari B; Mazzola R; Aiello D; Fersino S; Gregucci F; Alongi P; Nicodemo M; Cavalleri S; Salgarello M; Alongi F
Radiol Med; 2018 Sep; 123(9):719-725. PubMed ID: 29687208
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.
Li JR; Chiu KY; Wang SS; Yang CK; Chen CS; Ho HC; Hung CF; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Chang CH; Hsu CY; Ou YC
Front Pharmacol; 2017; 8():836. PubMed ID: 29213237
[No Abstract] [Full Text] [Related]
19. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.
Eder M; Neels O; Müller M; Bauder-Wüst U; Remde Y; Schäfer M; Hennrich U; Eisenhut M; Afshar-Oromieh A; Haberkorn U; Kopka K
Pharmaceuticals (Basel); 2014 Jun; 7(7):779-96. PubMed ID: 24983957
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
